Atopic Dermatitis News and Research

RSS

Atopic dermatitis is a long-term skin disease. "Atopic" refers to a tendency to develop allergy conditions. "Dermatitis" means swelling of the skin. Atopic dermatitis is most common in babies and children. But it can happen to anyone. People who live in cities and dry climates may be more likely to get this disease. When children with atopic dermatitis grow older, this problem can improve or go away. But the skin may stay dry and easy to irritate. At other times, atopic dermatitis is a problem in adulthood. You can't "catch" the disease or give it to other people.

Key triggers for food allergies in children after organ transplants

Study reviews transplant-acquired food allergies, focusing on pediatric patients, particularly liver transplant recipients. It explores immune system dysfunction, immunosuppressive agents, and gut microbiota changes as contributors to the rise of food allergies after organ transplants.

23 Sep 2024

Cardiovascular disease pathways associated with psoriasis, but not other immune-mediated diseases

A genetic connection between cardiovascular disease and psoriasis highlights shared inflammatory pathways, emphasizing the need for cardiovascular monitoring.

19 Sep 2024

New insights into AD pathogenesis and treatment

The main text of the study details the experiments conducted to understand the role of IL-24 in AD-like conditions. It describes the methods used, including single-cell RNA sequencing, and the animal models employed to mimic AD. The findings indicate that MRSA infection leads to increased IL-24 in keratinocytes, which in turn heightens type 2 immune responses and worsens AD symptoms.

29 Aug 2024

New insights on how melanoma cells resist cancer immunotherapy

Immune checkpoint inhibitors are cancer fighting drugs that help the immune system do its job of detecting and attacking tumor cells.

27 Aug 2024

Maintaining healthy weight could lower risk of immune-mediated skin diseases in kids

Childhood obesity can contribute to the development of common immune-mediated skin diseases (IMSDs), such as alopecia areata, atopic dermatitis, and psoriasis, new research finds.

21 Aug 2024

Novel molecular signaling pathway found to play a crucial role in maintaining the skin barrier

Our skin–the body's largest organ–provides the first line of defense against infections and many other threats to our health.

9 Aug 2024

Pomegranate peel extract restores skin balance, fights infections

Pomegranate peel extract effectively restores skin microbiota balance by reducing Staphylococcus aureus and promoting Staphylococcus epidermidis growth, showcasing its potential as a non-toxic antimicrobial treatment.

5 Aug 2024

Duke-NUS scientist awarded major funding to develop therapeutics for chronic inflammation

Associate Professor Lena Ho from Duke-NUS Medical School has been awarded US$1.85 million (approx. S$2.51 million) to further her team's research in developing microproteins into therapeutic targets to treat chronic inflammation.

29 Jul 2024

Study suggests limiting oral corticosteroid use to 90 days reduces adverse effects in atopic dermatitis patients

Researchers evaluated the association between long-term oral corticosteroid use and adverse events in adult patients with atopic dermatitis.

24 Jul 2024

Duke-NUS unveils LIVE Ventures to catalyze the commercialization of academic research

Duke-NUS Medical School today launched LIVE Ventures, a S$20 million incubation programme designed to catalyse the commercialisation of innovative academic research.

22 Jul 2024

Chronic Urticaria: Addressing unmet needs, emerging therapies, and advances in personalized treatment approaches

Emerging personalized treatment approaches for chronic urticari.

16 Jul 2024

Almirall's Ebglyss recommended by NICE for NHS atopic dermatitis patients

Almirall S.A., a global biopharmaceutical company dedicated to medical dermatology, announced today that the National Institute for Health and Care Excellence (NICE) has recommended Ebglyss (lebrikizumab) for use in moderate to severe Atopic Dermatitis in the NHS England.

13 Jul 2024

FDA approved PDE4 inhibitor roflumilast for atopic dermatitis

On July 9th, 2024, the U.S. FDA approved Arcutis Biotherapeutics' ZORYVE® (roflumilast) for treating atopic dermatitis (AD), the most common type of eczema affecting millions in the U.S. This once-daily, steroid-free cream could become a new standard of care for AD.

From Sino Biological Inc. 12 Jul 2024

Researchers identify molecular processes crucial for the maturation of Group 2 innate lymphoid cells

Scientists have discovered a novel mechanism of ILC2 immune cell development which may be involved in exacerbating allergic diseases.

11 Jul 2024

Archaeal, fungal, viral, as well as bacterial, functional makers for autism spectrum disorder in children

Researchers investigated the associations between multikingdom gut microbiome components and functional markers with autism spectrum disorder through metagenomic sequencing of children's fecal samples.

11 Jul 2024

Innovative aptamer cream shows promise in treating allergic contact dermatitis in mice

Researchers at the University of Bonn have isolated a DNA molecule that is suitable for combating allergic contact dermatitis in mice.

4 Jul 2024

NIAID scientists discover probiotic treatment for eczema

NIAID research has led to the availability of a new over-the-counter topical eczema probiotic.

26 Jun 2024

“G900” gene enhancers may play a pivotal role in asthma-associated inflammation

Type-2 helper T (Th2) cells play intricate roles in the inflammatory response underlying asthma. Elevated levels of the protein GATA3 stimulate the maturation of these cells. Consequently, gene regions known as enhancers, which enhance the expression of the GATA3 gene, have been implicated in asthma-associated inflammation.

26 Jun 2024

Study links gene regulation to allergic airway inflammation

Asthma patients experience respiratory distress due to allergens like house dust mites or pollen. However, the various triggers for asthma share a common pathway involving the release of proteins called type-2 cytokines by Type-2 helper T (Th2) cells and group-2 innate lymphoid cells (ILC2s). Both Th2 and ILC2 require high amounts of GATA-binding protein 3 (GATA3) for their maturation.

25 Jun 2024

Breathing New Life into Diagnostics: Plasmion's SICRIT® Technology

Revolutionizing Non-Invasive Diagnostics with Plasmion’s SICRIT Breath Analysis.

From Plasmion 11 Jun 2024